Livanova PLC

LivaNova PLC reported robust second-quarter 2026 financial results, exceeding revenue expectations and prompting an increase in full-year guidance, alongside a significant supply chain agreement.

LivaNova PLC's 2026 Annual General Meeting saw overwhelming shareholder approval for all ten proposals, including director elections, executive compensation, auditor ratification, and share repurchase authorizations.

LivaNova PLC reported strong first-quarter 2026 results, with revenue growth of 14.3% and raised full-year guidance for both revenue and adjusted diluted EPS.

LivaNova PLC announced robust double-digit revenue growth for full-year 2025, alongside positive 2026 guidance and key regulatory approvals.

LivaNova PLC announced the resignation of its Senior Vice President, Chief Legal Officer, and Company Secretary, Michael Hutchinson, effective January 26, 2026.

LivaNova PLC reported strong third-quarter 2025 results with double-digit revenue growth and raised its full-year 2025 financial guidance across key metrics.

LivaNova PLC's Q2 2026 filing shows robust revenue increases in both Cardiopulmonary and Neuromodulation segments, alongside improved net income, though litigation provisions and R&D expenses present ongoing considerations.

LivaNova PLC reports a net income of $22.3 million for Q1 2026, a significant turnaround from a $327.3 million loss in Q1 2025, driven by strong revenue growth in both Cardiopulmonary and Neuromodulation segments.

LivaNova reports strong revenue growth in Q3 2025, driven by Cardiopulmonary and Neuromodulation segments, but faces a significant net loss for the nine-month period due to a large environmental liability.

LivaNova reported strong revenue and operating income growth in Q2 2025, overshadowed by a significant one-time environmental liability charge from the SNIA litigation.

LivaNova PLC reports its Q1 2025 results, showing revenue growth but a significant net loss due to a substantial charge related to the SNIA environmental liability.

LivaNova PLC's Q3 2024 results show a significant increase in revenue and a return to profitability, driven by strong performance in its Cardiopulmonary and Neuromodulation segments.

LivaNova PLC reported a significant net loss of $242.5 million for 2025, primarily driven by a substantial SNIA environmental liability, despite strong revenue growth in its core Cardiopulmonary and Neuromodulation segments.

LivaNova PLC's 2024 10-K filing reveals a year of strategic restructuring, revenue growth in Cardiopulmonary and Neuromodulation segments, and ongoing management of cybersecurity incidents and legal proceedings.

LivaNova PLC's 10-K filing outlines the company's share structure, dividend policies, voting rights, and compliance with UK and US regulations.

Ahmet Tezel, Chief Innovation Officer of LivaNova PLC, sold 2,675 shares of common stock on August 11, 2026 for $77.74 per share.

LivaNova PLC director Peter M. Wilver reported transactions involving ordinary shares and restricted stock units on June 15, 2026.

LivaNova PLC director Todd C. Schermerhorn reported transactions involving ordinary shares and restricted stock units on June 15, 2026.

LivaNova PLC director Francesco Bianchi reported transactions involving ordinary shares and restricted stock units on June 15, 2026.

LivaNova PLC Director Susan M. Podlogar reported transactions involving ordinary shares and restricted stock units on June 15, 2026.

LivaNova PLC director Barry James Christopher reported transactions involving ordinary shares and restricted stock units on June 15, 2026.

LivaNova PLC has announced its 2026 Annual General Meeting of Shareholders, scheduled for June 10, 2026, to elect directors, approve executive compensation, and ratify auditor appointments.

LivaNova PLC announces its 2025 Annual General Meeting (AGM) to be held virtually on June 11, 2025, outlining proposals for shareholder voting, including the election of directors, executive compensation, and auditor ratification.

LivaNova PLC announces its 2025 Annual General Meeting (AGM) to be held virtually on June 11, 2025, detailing proposals for shareholder voting, including director elections, executive compensation, and auditor appointments.

LivaNova PLC is supplementing its proxy statement for the 2024 Annual General Meeting to include a non-binding advisory vote on the frequency of executive compensation votes.

LivaNova PLC's 2024 Annual General Meeting will be held virtually on June 11, 2024, with proxy materials available online.

LivaNova PLC announces its 2024 Annual General Meeting (AGM) to be held virtually on June 11, 2024, detailing proposals for director elections, executive compensation, auditor ratification, and incentive plan amendments.

Millennium Management and affiliated entities have reported a 4.4% beneficial ownership stake in LivaNova PLC.

PRIMECAP Management Co./CA/ has filed an Amendment No. 8 to Schedule 13G, disclosing a 7.74% beneficial ownership in LivaNova PLC as of December 31, 2025.

Millennium Management and affiliated entities report a 6.4% beneficial ownership stake in LivaNova PLC as of December 31, 2025.

Millennium Management LLC and affiliated entities have reported a 5.4% beneficial ownership stake in LivaNova PLC as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 12.7% beneficial ownership stake in LivaNova PLC's common stock.

Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, disclosing their beneficial ownership of 3.8% of LivaNova PLC's Ordinary Shares as of March 31, 2025.